Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBIT (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of EBIT data on record, last reported at -$42.2 million in Q4 2025.

  • For Q4 2025, EBIT fell 619.41% year-over-year to -$42.2 million; the TTM value through Dec 2025 reached -$157.9 million, down 435.87%, while the annual FY2025 figure was -$157.9 million, 435.87% down from the prior year.
  • EBIT reached -$42.2 million in Q4 2025 per TRDA's latest filing, up from -$47.1 million in the prior quarter.
  • Across five years, EBIT topped out at $53.4 million in Q2 2024 and bottomed at -$47.1 million in Q3 2025.
  • Average EBIT over 4 years is -$13.2 million, with a median of -$21.7 million recorded in 2024.
  • Peak YoY movement for EBIT: surged 465.28% in 2024, then crashed 619.41% in 2025.
  • A 4-year view of EBIT shows it stood at -$25.6 million in 2022, then surged by 119.18% to $4.9 million in 2023, then plummeted by 219.61% to -$5.9 million in 2024, then plummeted by 619.41% to -$42.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$42.2 million in Q4 2025, -$47.1 million in Q3 2025, and -$46.8 million in Q2 2025.